CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
BioPharma DiveBen FidlerNovember 16, 2026
CG s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street s expectations and lifting company shares.